# Eloralintide > Eli Lilly’s once-weekly selective amylin receptor agonist — Phase 2 reported up to 20.1% weight loss at 48 weeks; Phase 3 ENLIGHTEN began in 2026. - Also known as: LY3841136 - Class: Metabolic - FDA approved: No - Canonical page: https://americanpeptide.com/catalog/eloralintide ## Overview Eloralintide is an investigational once-weekly agonist selective for the amylin receptor, developed by Eli Lilly as a non-incretin obesity therapy and as a partner for tirzepatide. Its Phase 2 trial, reported in November 2025, showed up to 20.1% mean weight reduction at 48 weeks versus 0.4% on placebo — the largest effect reported for an amylin agonist alone. The Phase 3 ENLIGHTEN program began in February 2026, and a tirzepatide combination is advancing separately. It is not approved. Amylin receptors are not single proteins: they are the calcitonin receptor combined with one of three accessory proteins (RAMPs). First-generation long-acting analogs such as cagrilintide activate both the amylin receptors and the bare calcitonin receptor. Eloralintide was designed to favor the amylin receptors — a selectivity Lilly proposes may improve tolerability, though that has not been tested head-to-head. The Phase 2 dose-ranging trial in adults with obesity or overweight, reported in November 2025, showed mean weight reductions from roughly 9% up to 20.1% at 48 weeks across doses, versus 0.4% on placebo. That moved amylin agonism from "combination partner" to a plausible standalone therapy, with weight loss in the range of injectable semaglutide. Lilly opened the Phase 3 ENLIGHTEN program in February 2026, including a trial in obesity without diabetes and one in people with persistent obesity despite a weekly incretin. In September 2026 the company reported a Phase 2b study of eloralintide with tirzepatide ("EloraTZP") in which the highest dose produced 23.3% mean weight reduction at 48 weeks in adults with obesity and type 2 diabetes — a population in which weight loss is usually harder — with more gastrointestinal events in the combination arms. Phase 3 for the combination was planned for late 2026. ## Mechanism Selective agonism at amylin receptors (calcitonin receptor paired with RAMPs), with less activity at the calcitonin receptor alone → hindbrain satiety signaling and slowed gastric emptying, independent of the GLP-1 receptor. ## Chemistry | Property | Value | | --- | --- | | Molecular formula | C201H319N49O65S2 | | Molecular weight | 4526 Da | | PubChem CID | [175663130](https://pubchem.ncbi.nlm.nih.gov/compound/175663130) | ## Research areas Studied in: Obesity, Type 2 diabetes, Amylin pathway, Combination metabolic therapy. Guides on this site: - [Weight Loss & Metabolic Health](https://americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss. ## Key research - Selective amylin receptor agonism — designed to favor amylin receptors over the calcitonin receptor alone. - Phase 2 monotherapy (reported November 2025) — up to 20.1% mean weight reduction at 48 weeks versus 0.4% placebo. - Combination with tirzepatide — a Phase 2b study (reported September 2026) showed 23.3% mean weight reduction at the highest dose in adults with obesity and type 2 diabetes. - Phase 3 — the ENLIGHTEN program began in February 2026, including a trial in people already on incretin therapy. - Status — investigational; no Phase 3 results yet. ## FAQs ### What is eloralintide? Eloralintide (LY3841136) is an investigational once-weekly selective amylin receptor agonist from Eli Lilly, studied for obesity alone and in combination with tirzepatide. ### How much weight do people lose on eloralintide? The Phase 2 trial reported up to 20.1% mean weight reduction at 48 weeks versus 0.4% on placebo. Phase 3 results are not yet available. Population means, not individual predictions. ### Is eloralintide a GLP-1 drug? No. It acts on amylin receptors, a separate satiety pathway. It is grouped with the GLP-1 agents because it targets the same condition and is being developed as a partner for them. ### How is it different from cagrilintide? Both are long-acting amylin-pathway agonists. Cagrilintide activates amylin and calcitonin receptors and is mainly developed with semaglutide as CagriSema; eloralintide is designed to be more selective for amylin receptors and reported larger monotherapy weight loss in Phase 2. No head-to-head trial exists. ### Is eloralintide approved? No — it is investigational, with Phase 3 trials that began in 2026. This page is a research reference, not medical advice. ## Latest research Recent trials and publications mentioning Eloralintide, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily). ### Recent trials - [Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight](https://clinicaltrials.gov/study/NCT07353931) — RECRUITING · PHASE3 · NCT07353931 - [A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin](https://clinicaltrials.gov/study/NCT07392190) — RECRUITING · PHASE3 · NCT07392190 - [A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes](https://clinicaltrials.gov/study/NCT07881458) — RECRUITING · PHASE3 · NCT07881458 - [A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight](https://clinicaltrials.gov/study/NCT07369011) — RECRUITING · PHASE3 · NCT07369011 - [A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes](https://clinicaltrials.gov/study/NCT07282600) — RECRUITING · PHASE3 · NCT07282600 - [A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk](https://clinicaltrials.gov/study/NCT07900633) — NOT_YET_RECRUITING · PHASE3 · NCT07900633 --- Source: AmericanPeptide.com — https://americanpeptide.com/catalog/eloralintide Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com. Research reference only — computational and educational content, not medical advice.